Tempus AI vs Vanguard Ultra Short Bond ETF — how do they compare? Tempus AI trades at $49.1 (market cap $8.69B), while Vanguard Ultra Short Bond ETF trades at $49.71. The key difference: Vanguard Ultra Short Bond ETF is trading nearer its 52-week high, Tempus AI nearer its low. Which is the better fit depends on your goals.
| TEM | VUSB | |
|---|---|---|
Market Cap | $8.69B | — |
Sector | Broad Market / Factor | Leveraged / Inverse |
52-Week High | $103.25 | $50.03 |
52-Week Low | $42.37 | $49.60 |
Enterprise Value | $9.37B | — |
Signals from Pluang's Aura AI — not financial advice
Tempus AI (TEM) trades at $48.41, down 7.74% in the last 24 hours, reflecting a bearish technical signal. The company reported revenue of $1.27 billion in 2025 but a net loss of $245.03 million, with negative profitability metrics. Recent news highlights growth in AI-driven diagnostics and data services, including FDA approvals and research collaborations. The stock is trading well below the analyst consensus price target of $68.50, with a majority of analysts maintaining a Buy rating.
The outlook for TEM is a mix of high growth potential in healthcare AI and significant financial risk due to persistent losses. Investment opportunity lies in its proprietary data platform and expanding market reach, but risks include execution challenges and cash burn. Wall Street sentiment remains positive on long-term prospects, but investors should weigh the volatility against the company's unproven path to profitability.
VUSB trades at $49.70, up 0.02% on the day, with a bullish technical signal driven by positive momentum indicators. The ETF offers a yield of approximately 4.35%, positioning it as an alternative to money-market funds. Recent dividend payments include $0.18 in April 2026 and $0.17 in May 2026, with another $0.18 scheduled for July 2026.
The outlook for VUSB is supported by potential Federal Reserve rate increases enhancing short-term bond appeal, but risks include credit and duration exposure. The ETF remains a conservative income vehicle amid a non-inverted yield curve, though its technicals show mixed signals with overbought short-term RSI.
Trailing returns across standard periods
Latest headlines on both assets
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →VUSB is an actively managed ETF from Vanguard that invests in a diversified portfolio of high-quality, investment-grade fixed income securities with maturities typically under two years. It is designed to offer higher yield potential than traditional money market funds while maintaining limited price volatility, making it a strategic tool for managing short-term reserves with a 6-to-18-month horizon.
Read more on VUSB →